Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of zanubrutinib, rituximab, and venetoclax combination regimen in previously untreated follicular lymphoma: A Phase II trial from the bbc study

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJinhong ShiYLYang Liu

Discussion

Loading...

Member takes

Overview

Phase II clinical trial shows improved complete response rates and safety in untreated follicular lymphoma patients, emphasizing the role of kinase inhibitors.

Key Points

  • Assess the efficacy and safety of a combination treatment for previously untreated follicular lymphoma.
  • Single-center, open-label, single-arm phase II clinical trial
  • 30 patients aged ≥18 years with previously untreated follicular lymphoma
  • 3 cycles of zanubrutinib and rituximab followed by potential addition of venetoclax for incomplete responders
  • 100% complete response rate among 3 treated patients at end of treatment
  • Median progression-free survival hasn't been reached yet
  • Favorable safety profile with most adverse events being grade 1 or 2

Cite This Study

Shi et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da2ahttps://doi.org/10.1182/blood-2025-7108
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025
  2. 2Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma2025 · 1 citations
  3. 3A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study2025
  4. 4Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  5. 5Efficacy and safety of zanubrutinib combination therapy and monotherapy maintenance in patients with follicular lymphoma: A retrospective single-center analysis2025